logo-loader
AIM:FARN

Faron Pharmaceuticals Limited

Receive alerts
Market:
AIM
Price
175.00 GBX
Day Change
25.00%
Market Cap:
£120.41 m
52 weeks high
370.00
52 weeks low
120.00

In brief

Faron Pharmaceuticals Limited is a clinical-stage biopharmaceutical company based in Finland and the United States, with a focus on developing bexmarilimab, a first-in-class, humanized antibody that binds the Clever-1 target on myeloid cells and macrophages.

Clever-1 is an immunosuppressive receptor that promotes tumour growth and metastases when expressed on macrophages

Bexmarilimab primes the tumour microenvironment for optimal antitumour immune responses, in both hematological malignancies and solid tumours.

Snapshot

  • Faron Pharma rallies 28% following ‘remarkable’ Phase 1 data
  • Faron Pharmaceuticals enjoys momentum as COVID-19 drug candidate gets green light for late-stage trials
  • Faron Pharma data readout should provide more clarity - broker
  • Faron Pharmaceuticals reports promising phase 1 results from BEXMAB study